<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01003171</url>
  </required_header>
  <id_info>
    <org_study_id>MCS-2-US-pk</org_study_id>
    <nct_id>NCT01003171</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of MCS in Healthy Volunteers</brief_title>
  <acronym>MCS-2-US-pk</acronym>
  <official_title>An Open-Label, Multiple-Dose Study of MCS-2 to Examine the Pharmacokinetics of MCS and Other Components After Once-daily Oral Dosing in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Health Ever Bio-Tech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Health Ever Bio-Tech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to examine the pharmacokinetics, absorption and serum concentrations of MCS and
      other components after once-daily oral dosing of MCS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label, multiple-dose study, whose objective is to examine the
      pharmacokinetics of MCS and other components after once-daily oral dosing for 21 days.

      Subjects will undergo a 14-day washout phase and then enter the 21-day treatment phase.
      During the treatment phase, subjects will receive MCS, once-daily within one hour after the
      evening meal. After completion of the treatment phase, subjects will enter a post-treatment
      42-day washout phase. Throughout each of these phases, blood samples will be collected and
      assayed for concentrations of MCS and other components. The duration of protocol
      participation is expected to be 77 days for each eligible subject who completes the study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum MCS and other components levels</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>MCS-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCS-2 soft-gel capsule</intervention_name>
    <description>MCS-2 30 mg/day</description>
    <arm_group_label>MCS-2</arm_group_label>
    <other_name>MUS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal healthy volunteers

          -  18 years of age or older

        Exclusion Criteria:

          -  Subjects who can not comply with the study procedures or sign the informed consent
             form
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fu-Feng Kuo</last_name>
    <phone>+886-2-25788621</phone>
    <email>Healthe@ms76.hinet.net</email>
  </overall_contact>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2009</study_first_submitted>
  <study_first_submitted_qc>October 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2009</study_first_posted>
  <last_update_submitted>June 28, 2011</last_update_submitted>
  <last_update_submitted_qc>June 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2011</last_update_posted>
  <responsible_party>
    <name_title>Fu-Feng Kuo / General Manager</name_title>
    <organization>Health Ever Bio-Tech Co., Ltd.</organization>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>PK</keyword>
  <keyword>MCS</keyword>
  <keyword>Benign Prostatic Hyperplasia</keyword>
  <keyword>Multi-Carotenoids</keyword>
  <keyword>Healthy subjects</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

